Cotrimoxazole for community-acquired urinary tract infections leads to more adverse effects than fluoroquinolones - 08/05/21
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 3 |
| Iconographies | 0 |
| Vidéos | 0 |
| Autres | 0 |
Highlights |
• | Our study suggests that the fight against the emergence of multidrug-resistant bacteria can entail collateral damage, for both patients and the health care system. |
Abstract |
Background |
For several years, we applied an internal guideline for community-acquired urinary tract infections (cUTI), targeting the reduction of fluoroquinolone use (FQ) and thereby favouring cotrimoxazole (CTM) prescription. Our aim was to report adverse effects (AE) and outcome for patients presenting with cUTI and treated with these compounds.
Methods |
This cohort study was based on the dashboard of our department, bringing together 28 parameters for all patients, including diagnosis, microbiological data, antibiotic therapy, AE, length of hospital stay (LHS) and outcome. We included all patients with cUTI due to Enterobacteriaeae treated with CTM or FQ, and compared these 2 groups on in-hospital AE, LHS, and unfavourable outcome defined as intensive care requirement or death.
Results |
From June 2008 to June 2019, 640 cUTI due to Enterobacteriaeae were observed, among which 295 (46%) treated with CTM and 345 (54%) with a FQ. There were 25 AE (3.9%): 17 (5.7%) in the CTM group, and 8 (2.3%) in the FQ group (P=0.025). Adverse effects were associated with increased LHS compared to patients without AE: 11±6 vs. 7±4 days respectively, P<0.001, 11.4±6.2 days in the CTM group vs. 9.2±5.8 in the FQ group (relative LHS increase of 73.5% and 29.5%, respectively). Unfavorable outcome occurred for 1 patient (0.3%) in the CTM group, and 5 (1.4%) in the FQ group, P=0.297.
Conclusion |
Favouring cotrimoxazole for cUTI due to Enterobacteriaceae was associated compared to FQ with more AE and prolonged LHS. A cost-effectiveness analysis to validate such therapeutic strategy is warranted.
Le texte complet de cet article est disponible en PDF.Keywords : Urinary tract infection, Cotrimoxazole, Fluoroquinolone, Adverse effect, Outcome
Plan
Vol 51 - N° 4
P. 374-376 - juin 2021 Retour au numéro
Article précédent
- Clinical, biological and radiological features, 4-week outcomes and prognostic factors in COVID-19 elderly inpatients
- R. Palich, Y. Wakim, O. Itani, O. Paccoud, S. Boussouar, M. Lévy-Soussan, C. Soulie, N. Godefroy, A. Bleibtreu, on behalf of the PSL-Covid working group
- Does a 5-day course of antibiotics in elderly patients with community-acquired pneumonia achieve the established criteria of clinical stability?
- C. Flateau, M. Dinia, N. Raulet, S. Sayegh, S. Diamantis, M. Jager
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?